Suppose you were a business policy and strategy consultant during the time setting for the Genzyme case. You have been hired by Genzyme’s CEO to make recommendations to the company on which of the three initiatives (Malaria, Tuberculosis or Chagas) it should pursue. which of the three initiatives would you recommend, and which would you not recommend - from a strategic management perspective? Explain your choices and support your responses using provided data in the case.

How should Genzyme go about implementing your recommendations? What resources, capabilities, and core competencies should be used?